Industry Trend Analysis - New-Generation Insulin Products Will Be Major Revenue Earner For Novo Nordisk - DEC 2017
BMI View: Sales of Novo Nordisk ' s new-generation insulin products are expanding rapidly, and whilst these still comprise a small element of the firm ' s overall diabetes sales, the rate of increase is such that they can be expected to become a major component of the segment within a couple of years. Recent approvals for Tresiba in China and Fiasp in the US will provide a major commercial boost, strengthening Novo Nordisk ' s position as a significant insulin provider in two of the largest markets.
The China FDA has approved Novo Nordisk's Tresiba (insulin degludec) for the treatment of diabetes. Tresiba is a once-daily basal insulin with an ultra-long duration of action that allows for flexibility in day-to-day dosing. It provides significantly lower risk of overall, severe and nocturnal hypoglycaemia and comparable reductions of blood sugar levels compared to insulin glargine U100 in people with diabetes. Studies have also shown that Tresiba provides significantly lower variability in blood sugar levels compared to insulin glargine U100 and U300.
In the multinational, double-blind Tresiba cardiovascular outcomes trial, DEVOTE, Tresiba demonstrated cardiovascular safety and a reduced rate of severe and nocturnal severe hypoglycaemia by 40% and 53% respectively compared to insulin glargine U100 in people with Type II diabetes. In the double-blind SWITCH trials, Tresiba demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia compared to insulin glargine U100 in the full treatment period in people with Type I and Type II diabetes.
|Diabetes Essential To Sales|
|Novo Nordisk's Top-Line Quarterly Results (DKKmn)|
|Source: Novo Nordisk, BMI|